- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Summer 2016
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Femhrt | Warner Chilcott | Norethindrone Acetate and Ethinyl Estradiol Tablets | Lupin | indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis | 4/5/2016 |
Epivir | ViiV Healthcare | Lamivudine Tablets | Mylan | indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection | 4/6/2016 |
Lopressor | Novartis | Metoprolol Tartrate Tablets | Mylan | indicated for the treatment of hypertension | 4/11/2016 |
Glucerna Asceptic Adult Nutritional Shake (OTC) | Abbott Laboratories | Glucerna Asceptic Adult Nutritional Shake (OTC) | Perrigo | nutritional shake for people with diabetes | 4/12/2016 |
Zyvox | Pfizer | Linezolid Injection in Freeflex bags | Fresenius Kabi USA | indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial and Community-acquired pneumonia, Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, Uncomplicated skin and skin structure infections, and Vancomycin-resistant Enterococcus faecium infections | 4/21/2016 |
BenzaClin Pump Topical Gel | Valeant Pharmaceutical | Clindamycin Phosphate 1% / Benzoyl Peroxide 5% | Perrigo | indicated for the topical treatment of acne vulgaris | 5/2/2016 |
Mucinex DM ER Tablets (OTC) | Reckitt Benckiser | Guaifenesin / Dextromethorphan Hydrobromide ER Tablets (OTC) | Perrigo | indicated to control coughs and to break up mucus, making coughs more productive | 5/3/2016 |
Apresoline | Novartis | Hydralazine Hydrochloride Injection | Mylan | treatment of severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure | 5/5/2016 |
Lipofen | Cipher Pharmaceuticals | Fenofibrate Capsules | ANI Pharmaceuticals | indicated as an adjunct to diet: to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe hypertriglyceridemia | 5/9/2016 |
Frova | Endo Pharms | Frovatriptan Succinate Tablets | Mylan | treat acute migraine headaches in adults | 5/12/2016 |
Rowasa | Alaven Pharmaceuticals | Mesalamine rectal suspension enema | ANI Pharmaceuticals Inc. | indicated for treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis | 5/16/2016 |
Apresazide | Novartis | Hydralazine Hydrochloride Injection | Mylan | indicated for treatment of severe essential hypertension when the oral version of the drug cannot be given and there is in urgent need to lower blood pressure | 5/16/2016 |
Doryx | Mayne | Doxycycline Hyclate Delayed-Release (DR) Tablets, 200 mg. | Mylan | indicated as adjunctive therapy for severe acne | 5/23/2016 |
Flonase (OTC) | GlaxoSmithKline | Fluticasone 50 MCG Spray (OTC) | Hikma | indicated for the temporary relief of hay fever or for the upper respiratory allergies in adult and pediatric patients 4 years of age and older | 5/31/2016 |
Flonase (OTC) | GlaxoSmithKline | Fluticasone Propionate Nasal Spray (OTC) | Perrigo | indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and pediatric patients 4 years of age and older | 5/31/2016 |
Doxteric | Mayne | Doxycycline Hyclate Delayed-Release (DR) Tablets, 50 mg. | Mylan | indicated as adjunctive therapy for severe acne | 6/1/2016 |
Nuvigil | Cephalon | Armodafinil Tablets | Mylan | used to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, narcolepsy or shift-work disorder | 6/1/2016 |
Rythmol SR | GlaxoSmithKline | Propafenone Hydrochloride ER Capsules | Mylan | indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease | 6/2/2016 |
Vidaza | Celgene | Azacitidine for Injection | Mylan | indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia | 6/2/2016 |
Cleocin | Pharmacia and Upjohn | Clindamycin Palmitate Hydrochloride for Oral Solution | Mylan | indicated for treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate | 6/3/2016 |
OxyIR | Purdue Pharma | Oxycodone HCI Capsules | ANI Pharmaceuticals | indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate | 6/13/2016 |
Namenda | Forest Laboratories | Memantine Hydrochloride Tablets | Ajanta Pharma | anti-dementia drug | 6/14/2016 |
Avodart | GlaxoSmithKline | Dutasteride Capsules | Mylan | indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery | 6/24/2016 |
Imitrex | GlaxoSmithKline | Sumatriptan Injection | Teva / Antares Pharma | treat acute migraine with or without aura, and acute cluster headaches in adults | 6/27/2016 |
Lutera 28 | Alesse | Larissia | Amneal Pharmaceuticals | oral contraception | 6/29/2016 |
GENERICally Speaking Summer 2016
Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.